The New Delhi based Oncquest Laboratories is one of the India’s leading super specialized laboratory in molecular and clinical diagnostics. The company was recently selected as the winner of ‘Cancer Diagnostic Testing Laboratory of the Year’ under ASSOCHAM’s Women’s Health Excellence Awards 2017. In an exclusive interaction with the Biovoice News, Dr Ravi Gaur, Chief Operating Officer, Oncquest Laboratories shared his thoughts on the company’s latest activities, overall trends in the industry and policy. Read the excerpts below.
Please share your feelings on the company receiving ‘Cancer Diagnostic Lab of the Year Award’ recently?
It is a great achievement for each one of us. Getting an award from the Associated Chambers of Commerce of India (ASSOCHAM), is always an astounding experience. We are rejoicing the moment and are celebrating the honor accredited to us. However, this award has entrusted us with a sense of responsibility to work hard more in terms innovation and affordability in the field of cancer diagnostics.
What separates Oncquest from the other players in the market? How are you making the difference in the cancer diagnostics?
Oncquest’s approach is a bit different from other providers. We believe in providing very high quality and technology-driven comprehensive diagnostic solutions which are validated for the Indian population and that too at a highly affordable price. We remain committed to bring the most advanced technologies to India, validate them for the Indian environment and then ensure its availability to the masses at a very affordable price.
At Oncquest, we have one of the widest test portfolios in the diagnostic industry. With time, we have adapted ourselves to the market trends and customer requirements to develop tests based on the protocol requirements.
“Today, the diagnostics are more technology-driven and hence, we are moving from being a pure play hardware-driven business to a technology-enabled business. The use of clinical algorithms and IT algorithms to look at the treatment decisions is picking up”